



(12) Translation of
European patent specification

(11) NO/EP 3338781 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/5377 (2006.01)
A61P 25/24 (2006.01)
C07D 471/04 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2020.02.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.09.11
(86)	European Application Nr.	18154256.4
(86)	European Filing Date	2013.05.24
(87)	The European Application's Publication Date	2018.06.27
(30)	Priority	2012.05.25, US, 201261651669 P 2012.08.20, US, 201261691083 P 2012.10.19, US, 201261715907 P 2013.02.01, US, 201361759520 P 2013.03.14, US, 201361781629 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2854814, 2013.05.24
(73)	Proprietor	Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94025, USA
(72)	Inventor	HUNT, Hazel, Edenderry HouseBracken Close, Storrington, West Sussex, Storbritannia JOHNSON, Tony, 8/9 Spire Green CentreFlex Meadow, Harlow, Essex, Storbritannia RAY, Nicholas, 8/9 Spire Green CentreFlex Meadow, Harlow, Essex, Storbritannia WALTERS, Iain, BioCityPennyfoot Street, Nottingham, Nottinghamshire NG1 1GF, Storbritannia
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
(56)	References Cited:	WO-A1-2012/027702 WO-A1-2005/087769

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelse for anvendelse i behandling av en kreft valgt fra gruppen bestående av brystkreft, prostatakreft, eggstokkreft, hudkreft, hjernekreft, blærekreft, livmorhalskreft, leverkreft, lungekreft, leukemi, lymfom, nevroblastom og benkreft, idet forbindelsen har formelen:



10 hvori

R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R_{1a} ;

15 hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, N-oksid, C_{3-8} -sykloalkyl, og C_{3-8} -heterosykloalkyl;

ring J er valgt fra gruppen som består av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S;

20

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, C_{1-6} -alkyl- C_{1-6} -alkoksy, -CN, -OH, $-NR^{2a}R^{2b}$, $-C(O)R^{2a}$, $-C(O)OR^{2a}$, $-C(O)NR^{2a}R^{2b}$, $-SR^{2a}$, $-S(O)R^{2a}$, $-S(O)_2R^{2a}$, C_{3-8} -sykloalkyl, og C_{3-8} -heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substituert med 1-4 R^{2c} -grupper;

25

alternativt kombineres to R^2 -grupper knyttet til samme karbon for å danne en oksogruppe (=O);

alternativt kombineres to R^2 -grupper for å danne en heterosykloalkylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt

fra gruppen som består av N, O og S, hvori heterosykloalkylringen eventuelt er substituert med fra 1 til 3 R^{2d} -grupper;

R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} -alkyl;

5 hver R^{2c} er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, og $-NR^{2a}R^{2b}$;

hver R^{2d} er uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} -alkyl, eller to R^{2d} -grupper knyttet til det samme ringatomet kombineres for å danne (=O);

10 R^3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R^{3a} -grupper;

hver R^{3a} er uavhengig valgt fra gruppen som består av hydrogen, halogen og C_{1-6} -haloalkyl;

den senkede skriften n er et heltall fra 0 til 3;

15 eller salter derav.

2. Forbindelse for anvendelse ifølge krav 1, hvori

R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, C_{3-8} -sykloalkyl, og C_{3-8} -heterosykloalkyl;

ring J velges fra gruppen som består av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvori heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt gruppen som består av N, O og S;

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} -sykloalkyl, og C_{3-8} -heterosykloalkyl, hvori heterosykloalkylgruppene eventuelt er substituert med 1-4 R^{2c} -grupper;

R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} -alkyl;

hver R^{2c} er uavhengig valgt fra gruppen som består av hydrogen, halogen, hydroksy, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, og $NR^{2a}R^{2b}$;

R^3 er valgt fra gruppen som består av fenyl og pyridyl, hver eventuelt substituert med 1-4 R^{3a} -grupper;

5 hver R^{3a} er uavhengig valgt fra gruppen som består av hydrogen, halogen, og C_{1-6} -haloalkyl; og

den senkede skriften n er et heltall fra 0 til 3.

3. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 2,
10 hvori:

(a) R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S, eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

15 hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, C_{1-6} -haloalkyl, og C_{1-6} -alkoksy;

ring J er valgt fra gruppen som består av tetrahydrofuran, fenyl og pyridyl;

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, $NR^{2a}R^{2b}$, C_{3-8} -sykloalkyl, og C_{3-8} -heterosykloalkyl;

20 R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen som består av hydrogen og C_{1-6} -alkyl;

R^3 er valgt fra gruppen som består av fenyl og pyridyl;

R^{3a} er F; og

den senkede skriften n er 0 eller 1.

25

4. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvor

R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer hver uavhengig valgt fra gruppen som består av N, O og S,
30 eventuelt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, C_{1-6} -haloalkyl, og C_{1-6} -alkoksy;

ring J er valgt fra gruppen som består av fenyl og pyridyl;

hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, halogen, C_{1-6} -haloalkyl, CN og C_{5-6} -heterosykloalkyl;

R^3 er valgt fra gruppen som består av fenyl og pyridyl; og

5 R^{3a} er F.

5. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 4, hvori R^1 er valgt fra gruppen som består av

(a) pyrrol, pyrazol, imidazol, triazol, tetrazol, furan, oksazol, isoksazol, 10 oksadiazol, tiofen, tiazol, isotiazol, tiadiazol, pyridin, pyrazin, pyrimidin og pyridazin;

valgfritt hvor R^1 velges fra gruppen bestående av

(b) 2-pyrrol, 3-pyrrol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 15 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 3-isoksazol, 4-isoksazol, 5-isoksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 3-isotiazol, 4-isotiazol, 5-isotiazol, 1,2,3-tiadiazol-4-yl, 1,2,3-tiadiazol-5-yl, 1,2,4-tiadiazol-3-yl, 1,2,4-tiadiazol-5-yl, 1,2,5-tiadiazol-3-yl, 20 1,3,4-tiadiazol-2-yl, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin, 6-pyrimidin, 3-pyridazin, 4-pyridazin, 5-pyridazin, og 6-pyridazin.

6. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 4, hvor R^1 er valgt fra gruppen bestående av pyrazol, imidazol, triazol, furan, oksazol, 25 oksadiazol, tiofen, tiazol, pyridin, pyrazin og pyrimidin;

valgfritt hvor R^1 er valgt fra gruppen bestående av 1-pyrazol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin og 6-pyrimidin. 30

7. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1, 2, 5 og 6, hvori hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoksy og C_{3-8} -heterosykloalkyl;
- 5 valgfritt hvori hver R^{1a} er uavhengig valgt fra gruppen som består av hydrogen, metyl, etyl, trifluormetyl og metoksy.
8. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1, 2 og 5 til 7, hvori ring J er valgt fra gruppen som består av heterosykloalkyl, aryl og heteroaryl;
- 10 valgfritt hvor ring J velges fra gruppen bestående av fenyl, pyridin, imidazol, pyrazol, triazol, tetrazol, tiadiazol, isotiazol, isoksazol, sykloheksyl, tetrahydrofuran og tetrahydro-2H-pyran.
9. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 8,
- 15 hvori ring J er fenyl.
10. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 8, hvori ring J er pyridyl.
- 20 11. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 og 5 til 10, hvor hver R^2 er uavhengig valgt fra gruppen som består av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, C_{1-6} -alkyl- C_{1-6} -alkoksy, -CN, $NR^{2a}R^{2b}$, $C(O)OR^{2a}$, $S(O)_2R^{2a}$, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl, hvori heterosykloalkylgruppen har 5-6 ringmedlemmer og 1 til 2
- 25 heteroatomer;
- valgfritt hvor hver R^2 uavhengig er valgt fra gruppen bestående av hydrogen, metyl, etyl, propyl, isopropyl, F, Cl, $-CF_3$, CH_2OMe , OMe, $OCHF_2$, -CN, $-NMe_2$, $-C(O)OH$, $-C(O)NMe_2$, $-S(O)_2Me$, pyrrolidin, piperidin og morfolin.
- 30 12. Forbindelse for anvendelse ifølge et hvilket som helst av kravene 1 til 11, hvori R^3 er 4-F-fenyl.

13. Forbindelse for anvendelse ifølge krav 1, hvori forbindelsen er valgt fra gruppen som består av:

- (R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-3-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyl-1,3,4-oksadiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-4-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(furan-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiofen-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrimidin-2-yl)metanon,
- 30 (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((3-fluorbenzyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- ((4aR)-1-(4-fluorfenyl)-6-(((R/S)-tetrahydrofuran-2-yl)metyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(o-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(6-((4-etylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 15 (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-metoksifyenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((4-metoksifyenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-4-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((6-metoksypyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((tetrahydro-2H-pyran-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(6-(sykloheksylsulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 15 (R)-(6-((3,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- (R)-(6-((1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((6-morfolinopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-4-(((1-(4-fluorfenyl)-4a-(tiazol-2-karbonyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)metyl)benzonitril,
- 30 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-1,2,4-triazol-5-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrazin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metoksypyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-5-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-fluorpyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- ((R)-1-(4-fluorfenyl)-6-((6-((R)-3-fluorpyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(6-((4-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((4-metoksy-3-metylfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-klor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(6-((2-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 15 (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(6-((4-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetoksy)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 25 (R)-(6-((3-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,5-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((6-metylpyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((3-klor-4-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 10 (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 15 (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 20 (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzoesyre,
- (R)-(1-(4-fluorfenyl)-6-((3-(metoksymetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((2,3,4-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,

- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 5 (R)-(6-((1-etyl-1H-pirazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(6-((1,5-dimetil-1H-pirazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metil-1H-pirazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 10 (R)-(1-(4-fluorfenyl)-6-((1-metil-1H-pirazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-metilfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((4-metil-3,4-dihidro-2H-pirido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(6-((2,3-dihidrobenzofuran-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 20 (R)-5-((1-(4-fluorfenyl)-4a-(4-metilpikolinoyl)-4a,5,7,8-tetrahidro-1H-pirazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metilindolin-2-on,
- (R)-(1-(4-fluorfenyl)-6-((3-(metilsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(6-((1,3-dimetil-1H-pirazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 25 (R)-(6-((2,3-dihidrobenzo[b][1,4]dioksin-6-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(4-metilpyridin-2-yl)metanon,
- 30 (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahidro-1H-pirazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

- (R)-3-((4a-(4-ethylpikolinoyl)-1-(4-fluorfenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,
- (R)-(4-ethylpyridin-2-yl)(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- 5 (R)-3-((1-(4-fluorfenyl)-4a-(4-methylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,
- (R)-(6-((3,5-dimetylisoksazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-methylpyridin-2-yl)metanon,
- (R)-(6-((1-ethyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-(1-fenyl-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-methylpyridin-2-yl)metanon,
- 15 (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-methylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-methylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-methylpyridin-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((4-klor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(6-((3-klor-4-methylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(2-(pyrrolidin-1-yl)pyridin-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-3-((1-(4-fluorfenyl)-4a-(4-(trifluormetyl)pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-klorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-1-(4-(trifluormetyl)fenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(6-((1,2-dimetyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1,2-dimetyl-1H-imidazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-(2-metoksyetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-pyrazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-metyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((2-ethyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

5 (R)-(6-((1-ethyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

10 (R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

15 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

20 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

25 (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,

(R)-(6-((1-ethyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,

30 (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,
- 5 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 10 (R)-(6-((3-fluor-4-metyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 15 (R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metylpyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,
- 20 (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(6-metylpyridin-2-yl)metanon,
- (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 30 (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metyltiazol-2-yl)metanon,

- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 5 (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-
- 10 heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- 15 (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-
- 20 heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- 25 (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo [3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon ,
- (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-
- 30 g]isokinolin-6(4H)-yl)sulfonyl)-N,N-dimetylbenzamid,
- (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

- (R)-pyridin-2-yl(1-(pyridin-3-yl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon,
- (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-fenyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 5 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(3,4-difluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((3,5-difluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(6-((6-(dimetylamino)pyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 10 (R)-5-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylpyridin-2(1H)-on,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, og
- 15 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, eller salter derav,
- eller forbindelsen velges fra gruppen som består av:
- 20 (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,
- (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- 25 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,
- (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,
- 30 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,

(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,

(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon ,

5 (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,

(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, eller


15 (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon.

14. Forbindelse for anvendelse ifølge et hvilket som helst av de foregående krav, hvor forbindelsen administreres i kombinasjon med et antineoplastisk middel.

20 15. Forbindelse for anvendelse ifølge krav 15, hvor nevnte antineoplastiske middel velges fra gruppen av taksaner, taksol, docetaksel, paklitaksel, actinomycin, antrasykliner, doxorubicin, daunorubicin, valrubicin, bleomycin og cisplatin.

25 16. Forbindelse for anvendelse i behandlingen av en kreft, hvor forbindelsen administreres i kombinasjon med et antineoplastisk middel valgt fra gruppen av taksaner, taksol, docetaksel, paklitaksel, actinomycin, antrasykliner, doxorubicin, daunorubicin, valrubicin, bleomycin og cisplatin, og forbindelsen har formelen:

21



hvor

5 R^1 er en heteroarylring som har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer, hvert uavhengig valgt fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper hver uavhengig valgt fra R^{1a} ;

hver R^{1a} er uavhengig valgt fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN, N-oksid, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl;

10 ring J velges fra gruppen bestående av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvor heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringmedlemmer og fra 1 til 4 heteroatomer, hvert uavhengig valgt fra gruppen bestående av N, O og S;

15 hver R^2 er uavhengig valgt fra gruppen bestående av hydrogen, C_{1-6} -alkyl, halogen, C_{1-6} -haloalkyl, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, C_{1-6} -alkyl- C_{1-6} -alkoksy, -CN, -OH, -NR^{2a}R^{2b}, -C(O)R^{2a}, -C(O)OR^{2a}, -C(O)NR^{2a}R^{2b}, -SR^{2a}, -S(O)R^{2a}, -S(O)₂R^{2a}, C_{3-8} -sykloalkyl og C_{3-8} -heterosykloalkyl, hvor heterosykloalkylgruppene valgfritt er substituert med 1-4 R^{2c} -grupper;

20

alternativt kombineres to R^2 -grupper som er koblet til det samme karbon, for å danne en okso-gruppe (=O);

alternativt kombineres to R^2 -grupper for å danne en heterosykloalkylring som har fra 5 til 6 ringmedlemmer og fra 1 til 3 heteroatomer, hvert uavhengig valgt fra gruppen bestående av N, O og S, hvor heterosykloalkylringen valgfritt substitueres med fra 1 til 3 R^{2d} -grupper;

25

R^{2a} og R^{2b} er hver uavhengig valgt fra gruppen bestående av hydrogen og C_{1-6} -alkyl;

- hver R^{2c} velges uavhengig fra gruppen bestående av hydrogen, halogen, hydroksy, C_{1-6} -alkoksy, C_{1-6} -haloalkoksy, -CN og $-NR^{2a}R^{2b}$;
- hver R^{2d} velges uavhengig fra gruppen bestående av hydrogen og C_{1-6} -alkyl, eller to R^{2d} -grupper som er festet til det samme ringatom, kombineres for å danne (=O);
- 5 R^3 velges fra gruppen bestående av fenyl og pyridyl, hver valgfritt substituert med 1-4 R^{3a} -grupper;
- hver R^{3a} velges uavhengig fra gruppen bestående av hydrogen, halogen og C_{1-6} -haloalkyl;
- 10 n i senket skrift er et heltall fra 0 til 3;
- eller salter derav.